Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Bladder cancer: unmet need for novel therapies

Petros Grivas • 2 Jun 2019
ASCO 2019
Bladder Cancer Genitourinary Cancer Cisplatin Nivolumab

Petros Grivas, MD, PhD, of the Seattle Cancer Care Alliance, Seattle, WA, discusses the PrE0807 (NCT03532451) trial that investigated the feasibility of neoadjuvant nivolumab (N)/lirilumab (L) in cisplatin-ineligible muscle-invasive bladder cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Petros Grivas

1:08
Phase III clinical trials exploring targeted combination therapies for patients with UC
Petros Grivas • 20 Oct 2023
1:39
Phase Ib trial of bintrafusp alfa for advanced urothelial cancer
Petros Grivas • 20 Oct 2023
2:21
How junior physicians can develop a successful career in medical oncology
Petros Grivas • 20 Oct 2023
1:54
Innovations in treatment options for patients with BCG-unresponsive urothelial carcinoma
Petros Grivas • 20 Oct 2023

Related Videos

2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals